Daiichi won approval for Turalio on the strength of a 120-patient study that reported response rates of 39% for the study ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

The drug, developed with Japan's Daiichi Sankyo, showed an improvement in progression-free survival and overall survival in certain cancer patients regardless of their hormone receptor status.

Japan's Daiichi Sankyo has claimed its first worldwide approval ... 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients. ATL is a rare and highly ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

DS was established from the merger of Daiichi Pharmaceutical and Sankyo in 2005. As of 2021, we estimate over 60% of DS’ revenue comes from lucrative business lines, such as pain medication ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca ... In addition to informing viewers about the drug itself, Dan Switzer, head of Daiichi’s U.S. oncology business, recently told ...